Alseres Pharmaceuticals Expands Sites for the First Stage of the ALTROPANE(R) Phase III Clinical Tri...( HOPKINTON Mass. April 17 /- Alser...),Health

HOPKINTON, Mass., April 17 /PRNewswire-FirstCall/ -- Alseres Pharmaceuticals, Inc. (Nasdaq: ALSE) announced today that seven sites for the first stage of the ALTROPANE(R) Parkinson's or Essential Tremor - 2 (POET-2) Phase III clinical trial program are now open for patient enrollment. ALTROPANE molecular imaging agent is an investigational, diagnostic drug developed by Alseres to enable doctors to distinguish Parkinsonian Syndromes from non-Parkinsonian Syndromes in patients with tremor.

(Logo: http://www.newscom.com/cgi-bin/prnh/20070608/NEF043LOGO )

The POET-2 program is a two-part registration program, the first part of which is a clinical study designed to enroll up to 90 subjects with tremor in seven U.S. medical centers. The objective is to acquire the set of ALTROPANE images which will be used to train the expert readers, a customary practice for clinical trials of molecular imaging agents. The second part of the planned POET-2 program will involve two concurrent, replicate, multi-center Phase III trials using the optimized ALTROPANE imaging protocol Alseres developed for commercial use.

"Both the investigators and institutions participating in this study are among the best in the country," stated Mark Hurtt, M.D., Alseres Chief Medical Officer. "With their help, we are committed to advancing ALTROPANE toward regulatory approval and commercialization to aid in the diagnosis of Parkinson's Disease or Essential Tremor. If these trials are successful and the drug is approved, we believe that ALTROPANE could be a highly-selective central nervous system diagnostic molecular imaging agent -- and a valuable tool to help clinicians make
'/>"/>